James R. Neal's most recent trade in Processa Pharmaceuticals Inc was a trade of 203 Common Stock done . Disclosure was reported to the exchange on June 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Processa Pharma Inc | James R. Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 203 | 1,021 | - | - | Common Stock | |
| Processa Pharma Inc | James R. Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 203 | 5,249 | - | - | Restricted Stock | |
| Processa Pharma Inc | James R. Neal | Director | Purchase of securities on an exchange or from another person at price $ 2.53 per share. | 31 Mar 2026 | 789 | 818 | - | 2.5 | 2,000 | Common Stock |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2025 | 3,093 | 3,093 | - | - | Warrants to purchase ADRs | |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2025 | 3,093 | 3,093 | - | - | Pre-Funded Warrants to purchase ADRs | |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2025 | 2,473 | 2,473 | - | - | Warrants to purchase American Depositary Shares ("ADRs") | |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2025 | 2,473 | 2,473 | - | - | Pre-Funded Warrants to purchase ADRs | |
| Processa Pharma Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 300,000 | 300,000 | - | - | Stock Options (Right to Buy) | |
| Processa Pharma Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 100,000 | 100,000 | - | - | Restricted Stock Units | |
| Processa Pharma Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2025 | 175,299 | 206,505 | - | - | Restricted Stock | |
| Processa Pharma Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2025 | 31,206 | 36,275 | - | - | Restricted Stock | |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 4,464 | 4,464 | - | - | Series B Warrants (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 1.12 per share. | 06 Mar 2025 | 4,464 | 36,271 (0%) | 0% | 1.1 | 5,000 | American Depositary Shares representing Ordinary Shares |
| Akari Therapeutics PLC (ADR) | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 4,464 | 4,464 | - | - | Series A Warrants (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | R. James Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 2,000,000 | 24,216,000 (1%) | 0% | 0.0 | 1,000 | Ordinary Shares, par value $0.0001 per share |
| Processa Pharma Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 31,206 | 31,206 | - | - | Restricted Stock | |
| Palisade Bio Inc | R. Neal James | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 12,160 | 0 | - | - | Common Stock Options | |
| Palisade Bio Inc | Neal R. James | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 12,160 | 12,160 | - | - | Common Stock Options | |
| Palisade Bio Inc | R. James Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 6,880 | 0 | - | - | Common Stock Options | |
| Palisade Bio Inc | Neal James R. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 6,880 | 6,880 | - | - | Common Stock Options | |
| Palisade Bio Inc | James Neal R. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,820 | 10,920 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | R. Neal James | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,820 | 0 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Neal James R. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,100 | 5,100 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | R. James Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,100 | 0 | - | - | Restricted Stock Units | |
| Processa Pharma Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 101,365 | 101,365 | - | - | Restricted Stock | |
| Processa Pharma Inc | James R. Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2023 | 14,407 | 0 | - | - | Restricted Stock | |
| Processa Pharma Inc | James R. Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2023 | 14,407 | 14,407 | - | - | Common Stock | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2023 | 12,160 | 12,160 | - | - | Common Stock Options | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2023 | 5,100 | 5,100 | - | - | Restricted Stock Units | |
| Processa Pharma Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2022 | 17,797 | 17,797 | - | - | Restricted Stock | |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share. | 15 Jul 2022 | 25,000 | 36,822 (0%) | 0% | 4.0 | 100,750 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 25,000 | 218,056 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.55 per share. | 15 Jul 2022 | 20,883 | 15,939 (0%) | 0% | 29.6 | 617,095 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 31.19 per share. | 15 Jul 2022 | 3,212 | 12,727 (0%) | 0% | 31.2 | 100,175 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 31.86 per share. | 15 Jul 2022 | 905 | 11,822 (0%) | 0% | 31.9 | 28,834 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share. | 21 Mar 2022 | 50,000 | 61,822 (0%) | 0% | 4.0 | 201,500 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.00 per share. | 21 Mar 2022 | 50,000 | 11,822 (0%) | 0% | 29.0 | 1,450,250 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 50,000 | 106,250 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 2,339 | 103,911 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share. | 21 Mar 2022 | 2,339 | 14,161 (0%) | 0% | 4.0 | 9,426 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.02 per share. | 21 Mar 2022 | 2,339 | 11,822 (0%) | 0% | 30.0 | 70,209 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share. | 21 Mar 2022 | 1,111 | 12,933 (0%) | 0% | 4.0 | 4,477 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.02 per share. | 21 Mar 2022 | 1,111 | 11,822 (0%) | 0% | 30.0 | 33,348 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 1,111 | 102,800 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 60,000 | 60,000 | - | - | Non-Qualified Share Option (right to buy) |